JD Health International, Inc. (HK:6618)
:6618
Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$60.30
HK$0.45(1.61%)
At close: 4:00 PM EST
HK$60.30
HK$0.45(1.61%)
Day’s Range― - ―
52-Week RangeHK$37.20 - HK$71.70
Previous CloseN/A
Volume5.25M
Average Volume (3M)7.60M
Market Cap
HK$121.70B
Enterprise ValueHK$75.33B
Total Cash (Recent Filing)HK$47.00B
Total Debt (Recent Filing)HK$636.29M
Price to Earnings (P/E)19.4
Beta1.39
Next Earnings
Aug 13, 2026EPS Estimate
1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding3,211,075,200
10 Day Avg. Volume6,883,323
30 Day Avg. Volume7,596,953
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$71.75Price Target Upside18.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)1.82
Revenue Forecast (FY)HK$86.58B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExceptionally low leverage and rising equity provide durable financial flexibility. With debt-to-equity near 1% and ROE improving to ~8.7% in 2025, the company can fund growth, absorb shocks, and invest in supply chain and AI without relying on external financing, sustaining long-term stability.
Sustained Revenue And Margin ImprovementConsistent double-digit top-line growth and margin gains signal durable demand and improved unit economics. 2025 showed 26% revenue growth, non-IFRS profit +36.3% and gross margin +1.9ppt, indicating scalable operations and an earnings base that supports continued reinvestment and margin sustainability.
Scale And Supply-chain Competitive AdvantageControl of an efficient pharmaceutical supply chain, integration with JD logistics, ~300 self-operated pharmacies and a ~220m active user base create durable scale advantages. These reduce fulfillment costs, support direct-sales margins, and raise barriers to entry for smaller rivals over the medium term.
Bears Say
Free-cash-flow ResetA 2025 FCF reset to zero after years of positive free cash flow reduces financial optionality. Even with strong operating cash, stepped-up capex or working-capital needs can constrain dividends, buybacks, or M&A capacity and increase sensitivity to any revenue or margin softness.
Revenue Concentration In Direct SalesWith ~83% of revenue from direct sales, the business is exposed to supplier, category or pricing shifts in those channels. That concentration raises execution risk and margin volatility versus a more balanced service/product mix, making diversification of service revenue strategically important.
AI Monetization UncertaintyHigh engagement with AI products (e.g., Dr. Da Wei) has not yet translated reliably into revenue. The unclear commercialization path for doctor-facing and B2B AI services means large R&D and deployment costs may take time to generate sustainable margins, delaying returns on investment.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$37.20 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$121.70B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 65 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Mar 05, 2026. The company reported HK$1.083 earnings per share for the quarter, beating the consensus estimate of HK$0.753 by HK$0.33.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.35.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,211,075,200 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.083 in its last earnings report, beating expectations of HK$0.753. Following the earnings report the stock price went down -6.219%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$71.75 (18.99% Upside)
HK$71.75 (18.99% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.47%
12-Months-Change
Fundamentals
Return on Equity
9.11%
Trailing 12-Months
Asset Growth
19.80%
Trailing 12-Months
Company Description
JD Health International, Inc.
JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$71.75
▲(18.99% Upside)
Technical Analysis
Kindstar Globalgene Technology, Inc.
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---